{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T13:42:57Z","timestamp":1770126177130,"version":"3.49.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04470-x","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T01:26:39Z","timestamp":1770081999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systematic review of multimodal management strategies for Insulinoma-Induced hypoglycaemia: current evidence and future directions"],"prefix":"10.1007","volume":"91","author":[{"given":"Elena","family":"Zago","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Citone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Canu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Pillozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Petrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3766-4682","authenticated-orcid":false,"given":"Clotilde","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"4470_CR1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000335591","volume":"95","author":"RT Jensen","year":"2012","unstructured":"R.T. Jensen, G. Cadiot, M.L. Brandi, De W.W. Herder, G. Kaltsas et al., ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 95, 98\u2013119 (2012)","journal-title":"Neuroendocrinology"},{"key":"4470_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.bpg.2005.06.002","volume":"19","author":"K \u00d6berg","year":"2005","unstructured":"K. \u00d6berg, B. Eriksson, Endocrine tumours of the pancreas. Best Pract. Res. Clin. Gastroenterol. 19, 753\u2013781 (2005)","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"4470_CR3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S0025-6196(12)62083-7","volume":"66","author":"FJ Service","year":"1991","unstructured":"F.J. Service, M.M. McMAHON, P.C. O\u2019Brien, D.J. Ballard, Functioning Insulinoma\u2014Incidence, Recurrence, and Long-Term survival of patients: A 60-Year study. Mayo Clin. Proc. 66, 711\u2013719 (1991)","journal-title":"Mayo Clin. Proc."},{"key":"4470_CR4","first-page":"817","volume":"35","author":"A. Faggiano","year":"2012","unstructured":"A. Faggiano, P. Ferolla, F. Grimaldi, D. Campana, M. Manzoni et al., Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data froma large prospective and retrospective Italian epidemiological study: THE NETMANAGEMENT STUDY. J. Endocrinol. Invest. 35, 817-823 (2012)","journal-title":"J. Endocrinol. Invest."},{"key":"4470_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0002-9343(99)00021-2","volume":"106","author":"AM Dizon","year":"1999","unstructured":"A.M. Dizon, S. Kowalyk, B.J. Hoogwerf, Neuroglycopenic and other symptoms in patients with insulinomas. Am. J. Med. 106, 307\u2013310 (1999)","journal-title":"Am. J. Med."},{"key":"4470_CR6","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1210\/jc.2008-2031","volume":"94","author":"KA Placzkowski","year":"2009","unstructured":"K.A. Placzkowski, A. Vella, G.B. Thompson, C.S. Grant, C.C. Reading et al., Secular trends in the presentation and management of functioning Insulinoma at the Mayo Clinic, 1987\u20132007. J. Clin. Endocrinol. Metab. 94, 1069\u20131073 (2009)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4470_CR7","doi-asserted-by":"publisher","first-page":"e13318","DOI":"10.1111\/jne.13318","volume":"35","author":"J Hofland","year":"2023","unstructured":"J. Hofland, M. Falconi, E. Christ, J.P. Casta\u00f1o, A. Faggiano et al., European neuroendocrine tumor society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J. Neuroendocrinol. 35, e13318 (2023)","journal-title":"J. Neuroendocrinol."},{"key":"4470_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1530\/EJE-12-1101","volume":"168","author":"V Bernard","year":"2013","unstructured":"V. Bernard, C. Lombard-Bohas, M.-C. Taquet, F.-X. Caroli-Bosc, P. Ruszniewski et al., Efficacy of everolimus in patients with metastatic Insulinoma and refractory hypoglycemia. Eur. J. Endocrinol. 168, 665\u2013674 (2013)","journal-title":"Eur. J. Endocrinol."},{"key":"4470_CR9","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1507\/endocrj.EJ13-0025","volume":"60","author":"M Okamoto","year":"2013","unstructured":"M. Okamoto, M. Kishimoto, Y. Takahashi, K. Osame, H. Noto et al., A case of malignant insulinoma: successful control of glycemic fluctuation by replacing octreotide injections with octreotide LAR injections. Endocr. J. 60, 951\u2013957 (2013)","journal-title":"Endocr. J."},{"key":"4470_CR10","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1093\/annonc\/mdn351","volume":"19","author":"TR Halfdanarson","year":"2008","unstructured":"T.R. Halfdanarson, K.G. Rabe, J. Rubin, G.M. Petersen, Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann. Oncol. 19, 1727\u20131733 (2008)","journal-title":"Ann. Oncol."},{"key":"4470_CR11","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1210\/jc.2011-1563","volume":"96","author":"E Van Schaik","year":"2011","unstructured":"Van E. Schaik, Van E.I. Vliet, R.A. Feelders, E.P. Krenning, S. Khan et al., Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy. J. Clin. Endocrinol. Metab. 96, 3381\u20133389 (2011)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4470_CR12","first-page":"125","volume":"5","author":"S. Libutti","year":"2015","unstructured":"S. Libutti, A. Taye, Diagnosis and management of insulinoma: current best practice and ongoing developments. Res. Rep. Endocr. Disord. 5, 125\u2013133 (2015)","journal-title":"Res. Rep. Endocr. Disord"},{"key":"4470_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1634\/theoncologist.2012-0434","volume":"18","author":"JC Yao","year":"2013","unstructured":"J.C. Yao, D.R. Lagunes, M.H. Kulke, Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned. Oncologist. 18, 525\u2013532 (2013)","journal-title":"Oncologist"},{"key":"4470_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228\u2013247 (2009)","journal-title":"Eur. J. Cancer"},{"key":"4470_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1472-6947-7-16","volume":"7","author":"C Schardt","year":"2007","unstructured":"C. Schardt, M.B. Adams, T. Owens, S. Keitz, P. Fontelo, Utilization of the PICO framework to improve searching pubmed for clinical questions. BMC Med. Inf. Decis. Mak. 7, 16 (2007)","journal-title":"BMC Med. Inf. Decis. Mak."},{"key":"4470_CR16","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 339, b2700\u2013b2700 (2009)","journal-title":"BMJ"},{"key":"4470_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1507\/endocrj.EJ15-0428","volume":"63","author":"Y Komatsu","year":"2016","unstructured":"Y. Komatsu, A. Nakamura, M. Takihata, Y. Inoue, S. Yahagi et al., Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic hypoglycemia. Endocr. J. 63, 311\u2013314 (2016)","journal-title":"Endocr. J."},{"key":"4470_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2174\/092986706775527947","volume":"13","author":"J Hansen","year":"2006","unstructured":"J. Hansen, Towards selective Kir6.2\/SUR1 potassium channel Openers, medicinal chemistry and therapeutic perspectives. Curr. Med. Chem. 13, 361\u2013376 (2006)","journal-title":"Curr. Med. Chem."},{"key":"4470_CR19","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1136\/pgmj.73.864.640","volume":"73","author":"GV Gill","year":"1997","unstructured":"G.V. Gill, O. Rauf, I.A. MacFarlane, Diazoxide treatment for insulinoma: a National UK survey. Postgrad. Med. J. 73, 640\u2013641 (1997)","journal-title":"Postgrad. Med. J."},{"key":"4470_CR20","first-page":"136","volume":"122","author":"Q Gilliaux","year":"2022","unstructured":"Q. Gilliaux, C. Bertrand, F. Hanon, J.E. Donckier, Preoperative treatment of benign insulinoma: diazoxide or somatostatin analogues? Acta Chir. Belg. 122, 136\u2013139 (2022)","journal-title":"Acta Chir. Belg."},{"key":"4470_CR21","first-page":"760","volume":"13","author":"J Novotny","year":"2005","unstructured":"J. Novotny, F. Janku, P. Mares, L. Petruzelka, Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic Insulinoma. Support Care Cancer. 13, 760\u2013762 (2005)","journal-title":"Support Care Cancer"},{"key":"4470_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/978-3-642-81265-1_28","volume-title":"Glucocorticoid Hormone Action","author":"JH Exton","year":"1979","unstructured":"J.H. Exton, Regulation of gluconeogenesis by glucocorticoids, in Glucocorticoid Hormone Action, ed. by J.D. Baxter, G.G. Rousseau (Springer Berlin Heidelberg, Berlin, Heidelberg, 1979), pp. 535\u2013546"},{"key":"4470_CR23","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1210\/endo-127-4-1640","volume":"127","author":"J Philippe","year":"1990","unstructured":"J. Philippe, M. Missotten, Dexamethasone inhibits insulin biosynthesis by destabilizing insulin messenger ribonucleic acid in hamster insulinoma cells. Endocrinology. 127, 1640\u20131645 (1990)","journal-title":"Endocrinology"},{"key":"4470_CR24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s005950070124","volume":"30","author":"Y Tanaka","year":"2000","unstructured":"Y. Tanaka, H. Funahashi, T. Imai, T. Naruse, K. Suzumura et al., The effectiveness of administering a minimal dose of octreotide long-term prior to surgery for insulinoma: report of a case. Surg. Today. 30, 541\u2013543 (2000)","journal-title":"Surg. Today"},{"key":"4470_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1006\/frne.1999.0183","volume":"20","author":"YC Patel","year":"1999","unstructured":"Y.C. Patel, Somatostatin and its receptor family. Front. Neuroendocrinol. 20, 157\u2013198 (1999)","journal-title":"Front. Neuroendocrinol."},{"key":"4470_CR26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1530\/eje.1.01901","volume":"152","author":"D Vezzosi","year":"2005","unstructured":"D. Vezzosi, A. Bennet, P. Rochaix, F. Courbon, J. Selves et al., Octreotide in Insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur. J. Endocrinol. 152, 757\u2013767 (2005)","journal-title":"Eur. J. Endocrinol."},{"key":"4470_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12902-018-0325-4","volume":"18","author":"M Caliri","year":"2018","unstructured":"M. Caliri, V. Verdiani, E. Mannucci, V. Briganti, L. Landoni et al., A case of malignant Insulinoma responsive to somatostatin analogs treatment. BMC Endocr. Disord. 18, 98 (2018)","journal-title":"BMC Endocr. Disord"},{"key":"4470_CR28","first-page":"433","volume":"111","author":"E Del Pozo","year":"1986","unstructured":"Del E. Pozo, M. Neufeld, K. Schl\u00fcter, F. Tortosa, P. Clarenbach et al., Endocrine profile of a long-acting somatostatin derivative SMS 201\u2013995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol. (Copenh). 111, 433\u2013439 (1986)","journal-title":"Acta Endocrinol. (Copenh)"},{"key":"4470_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40618-019-01091-w","volume":"43","author":"I Maggio","year":"2020","unstructured":"I. Maggio, V. Mollica, N. Brighi, G. Lamberti, L. Manuzzi et al., The functioning side of the pancreas: a review on insulinomas. J. Endocrinol. Invest. 43, 139\u2013148 (2020)","journal-title":"J. Endocrinol. Invest."},{"key":"4470_CR30","doi-asserted-by":"publisher","first-page":"E769","DOI":"10.1152\/ajpendo.1997.272.5.E769","volume":"272","author":"H Yoshitomi","year":"1997","unstructured":"H. Yoshitomi, Y. Fujii, M. Miyazaki, N. Nakajima, N. Inagaki et al., Involvement of MAP kinase and c-fos signaling in the Inhibition of cell growth by somatostatin. Am. J. Physiol-Endocrinol Metab. 272, E769\u2013E774 (1997)","journal-title":"Am. J. Physiol-Endocrinol Metab."},{"key":"4470_CR31","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0959-8049(01)00073-9","volume":"37","author":"T Aparicio","year":"2001","unstructured":"T. Aparicio, M. Ducreux, E. Baudin, J.-C. Sabourin, De T. Baere et al., Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur. J. Cancer. 37, 1014\u20131019 (2001)","journal-title":"Eur. J. Cancer"},{"key":"4470_CR32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000091408","volume":"65","author":"S Romeo","year":"2006","unstructured":"S. Romeo, M. Milione, A. Gatti, M. Fallarino, V. Corleto et al., Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-Year-Old woman with a malignant Insulinoma positive for somatostatin receptors type 2. Horm. Res. Paediatr. 65, 120\u2013125 (2006)","journal-title":"Horm. Res. Paediatr."},{"key":"4470_CR33","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/j.1365-2265.2007.03136.x","volume":"68","author":"D Vezzosi","year":"2008","unstructured":"D. Vezzosi, A. Bennet, F. Courbon, P. Caron, Short- and long\u2010term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism. Clin. Endocrinol. (Oxf). 68, 904\u2013911 (2008)","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"4470_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1507\/endocrj.53.79","volume":"53","author":"H Kishikawa","year":"2006","unstructured":"H. Kishikawa, Y. Okada, A. Hirose, T. Tanikawa, K. Kanda et al., Successful treatment of Insulinoma by a single daily dose of octreotide in two elderly female patients. Endocr. J. 53, 79\u201385 (2006)","journal-title":"Endocr. J."},{"key":"4470_CR35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1507\/endocrj.52.629","volume":"52","author":"T Katabami","year":"2005","unstructured":"T. Katabami, H. Kato, N. Shirai, S. Naito, N. Saito, Successful Long-term treatment with Once-daily injection of Low-dose octreotide in an aged patient with Insulinoma. Endocr. J. 52, 629\u2013634 (2005)","journal-title":"Endocr. J."},{"key":"4470_CR36","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/pmj.78.924.623","volume":"78","author":"CEH Craig","year":"2002","unstructured":"C.E.H. Craig, I.W. Gallen, Possible functional regression of Insulinoma with prolonged octreotide. Postgrad. Med. J. 78, 623\u2013624 (2002)","journal-title":"Postgrad. Med. J."},{"key":"4470_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1365-2265.1995.tb01901.x","volume":"43","author":"R Gama","year":"1995","unstructured":"R. Gama, V. Marks, J. Wrlght, J.D. Teale, Octreotide exacerbated fasting hypoglycaemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon. Clin. Endocrinol. (Oxf). 43, 117\u2013120 (1995)","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"4470_CR38","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1517\/14740330903379525","volume":"8","author":"J Bornschein","year":"2009","unstructured":"J. Bornschein, I. Drozdov, P. Malfertheiner, Octreotide LAR: safety and tolerability issues. Expert Opin. Drug Saf. 8, 755\u2013768 (2009)","journal-title":"Expert Opin. Drug Saf."},{"key":"4470_CR39","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.pan.2014.07.011","volume":"14","author":"M Scharf","year":"2014","unstructured":"M. Scharf, D. Mueller, U. Koenig, A. Pfestroff, W. Nimphius et al., Management of a metastasized high grade Insulinoma (G3) with refractory hypoglycemia: case report and review of the literature. Pancreatology. 14, 542\u2013545 (2014)","journal-title":"Pancreatology"},{"key":"4470_CR40","doi-asserted-by":"publisher","first-page":"876","DOI":"10.2174\/1389200219666180328113801","volume":"19","author":"N Sawicka-Gutaj","year":"2018","unstructured":"N. Sawicka-Gutaj, M. Owecki, M. Ruchala, Pasireotide - Mechanism of action and clinical applications. Curr. Drug Metab. 19, 876\u2013882 (2018)","journal-title":"Curr. Drug Metab."},{"key":"4470_CR41","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0006-2952(99)00010-6","volume":"57","author":"Y Zambre","year":"1999","unstructured":"Y. Zambre, Z. Ling, M.-C. Chen, X. Hou, C.-W. Woon et al., Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem. Pharmacol. 57, 1159\u20131164 (1999)","journal-title":"Biochem. Pharmacol."},{"key":"4470_CR42","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"R.R. Henry, T.P. Ciaraldi, D. Armstrong, P. Burke, M. Ligueros-Saylan et al., Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J. Clin. Endocrinol. Metab. 98, 3446\u20133453 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4470_CR43","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s12020-020-02406-1","volume":"70","author":"F Sileo","year":"2020","unstructured":"F. Sileo, B. Cangiano, C. Cacciatore, J. Amar\u00f9, F. Gatto et al., Off-label Pasireotide treatment in one Insulinoma patient with an atypical presentation and intolerant to diazoxide. Endocrine. 70, 435\u2013438 (2020)","journal-title":"Endocrine"},{"key":"4470_CR44","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s12020-018-1818-7","volume":"64","author":"R Pivonello","year":"2019","unstructured":"R. Pivonello, G. Arnaldi, C. Scaroni, C. Giordano, S. Cannav\u00f2 et al., The medical treatment with Pasireotide in cushing\u2019s disease: an Italian multicentre experience based on real-world evidence. Endocrine. 64, 657\u2013672 (2019)","journal-title":"Endocrine"},{"key":"4470_CR45","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1517\/14656566.2016.1146688","volume":"17","author":"LE Wildemberg","year":"2016","unstructured":"L.E. Wildemberg, M.R. Gadelha, Pasireotide for the treatment of acromegaly. Expert Opin. Pharmacother. 17, 579\u2013588 (2016)","journal-title":"Expert Opin. Pharmacother"},{"key":"4470_CR46","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"M.R. Gadelha, M.D. Bronstein, T. Brue, M. Coculescu, M. Fleseriu et al., Pasireotide versus continued treatment with octreotide or Lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2, 875\u2013884 (2014)","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4470_CR47","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"A. Colao, S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu et al., A 12-Month phase 3 study of Pasireotide in cushing\u2019s disease. N Engl. J. Med. 366, 914\u2013924 (2012)","journal-title":"N Engl. J. Med."},{"key":"4470_CR48","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/cen.13503","volume":"88","author":"NS Hendren","year":"2018","unstructured":"N.S. Hendren, K. Panach, T.J. Brown, L. Peng, M.S. Beg et al., Pasireotide for the treatment of refractory hypoglycaemia from malignant Insulinoma. Clin. Endocrinol. (Oxf). 88, 341\u2013343 (2018)","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"4470_CR49","doi-asserted-by":"crossref","unstructured":"A. Tirosh, S. Stemmer, E. Solomonov, E. Elnekave, W. Saeger et al., (2015) Pasireotide for malignant insulinoma. HORMONES","DOI":"10.14310\/horm.2002.1639"},{"key":"4470_CR50","doi-asserted-by":"publisher","first-page":"860614","DOI":"10.3389\/fendo.2022.860614","volume":"13","author":"S Oziel-Taieb","year":"2022","unstructured":"S. Oziel-Taieb, J. Maniry-Quellier, B. Chanez, F. Poizat, J. Ewald et al., Pasireotide for refractory hypoglycemia in malignant Insulinoma- case report and review of the literature. Front. Endocrinol. 13, 860614 (2022)","journal-title":"Front. Endocrinol."},{"key":"4470_CR51","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.2147\/DDDT.S84177","volume":"9","author":"E. Wolin","year":"2015","unstructured":"E. Wolin, B. Jarzab, B. Eriksson, T. Walter, C. Toumpanakis et al., Phase III study of Pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des. Devel Ther. 9, 5075\u20135086 (2015)","journal-title":"Drug Des. Devel Ther."},{"key":"4470_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/ERC-14-0360","volume":"22","author":"M Cives","year":"2015","unstructured":"M. Cives, P.L. Kunz, B. Morse, D. Coppola, M.J. Schell et al., Phase II clinical trial of Pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr. Relat. Cancer. 22, 1\u20139 (2015)","journal-title":"Endocr. Relat. Cancer"},{"key":"4470_CR53","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40265-013-0052-0","volume":"73","author":"K McKeage","year":"2013","unstructured":"K. McKeage, Pasireotide: A review of its use in cushing\u2019s disease. Drugs. 73, 563\u2013574 (2013)","journal-title":"Drugs"},{"key":"4470_CR54","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1053\/snuc.2002.31027","volume":"32","author":"M De Jong","year":"2002","unstructured":"De M. Jong, R. Valkema, F. Jamar, L.K. Kvols, D.J. Kwekkeboom et al., Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl. Med. 32, 133\u2013140 (2002)","journal-title":"Semin Nucl. Med."},{"key":"4470_CR55","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s12020-020-02570-4","volume":"71","author":"WT Zandee","year":"2021","unstructured":"W.T. Zandee, J. Hofland, De W.W. Herder, Should everolimus be stopped after radiological progression in metastatic insulinoma? A pro point of view. Endocrine. 71, 256\u2013257 (2021)","journal-title":"Endocrine"},{"key":"4470_CR56","doi-asserted-by":"crossref","unstructured":"W.T. Zandee, T. Brabander, A. Blazevic, B.L.R. Kam, J.J.M. Teunissen, R.A. Feelders, J. Hofland,W.W. de Herder, Symptomatic and radiological response to 177Lu-DOTATATE for the treatmentof functioning pancreatic neuroendocrine tumors. J. Clin. Endocrinol. Metab. 104(4), 1336\u20131344 (2019)","DOI":"10.1210\/jc.2018-01991"},{"key":"4470_CR57","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1530\/EJE-09-1010","volume":"162","author":"GSY Ong","year":"2010","unstructured":"G.S.Y. Ong, D.E. Henley, D. Hurley, J.H. Turner, P.G. Claringbold et al., Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant Insulinoma. Eur. J. Endocrinol. 162, 1001\u20131008 (2010)","journal-title":"Eur. J. Endocrinol."},{"key":"4470_CR58","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2967\/jnumed.123.265894","volume":"65","author":"L Friebe","year":"2024","unstructured":"L. Friebe, M.T. Freitag, M. Braun, G. Nicolas, A. Bauman et al., Peptide receptor radionuclide therapy is effective for clinical control of symptomatic metastatic insulinoma: A Long-Term retrospective analysis. J. Nucl. Med. 65, 228\u2013235 (2024)","journal-title":"J. Nucl. Med."},{"issue":"4","key":"4470_CR59","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1530\/EJE-19-0989","volume":"182","author":"A. Veltroni","year":"2020","unstructured":"A. Veltroni, E. Cosaro, F. Spada, N. Fazio, A. Faggiano, A. Colao, S. Pusceddu, M.C. Zatelli, D. Campana, A. Piovesan, A. Pia, E.M. Grossrubatscher, A. Filice, A. Bianchi, P. Razzore, M. Toaiari, S. Cingarlini, L. Landoni, R. Micciolo, M.V. Dav\u00ec, Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study. Eur. J. Endocrinol. 182(4), 439\u2013446 (2020) https:\/\/doi.org\/10.1530\/EJE-19-0989","journal-title":"Eur. J. Endocrinol."},{"key":"4470_CR60","doi-asserted-by":"publisher","first-page":"e250091","DOI":"10.1530\/ERC-25-0091","volume":"32","author":"R Koch","year":"2025","unstructured":"R. Koch, P.W. McGarrah, A. Vella, P. Shah, T.J. Hobday et al., Comparative efficacy of systemic therapies in malignant Insulinoma. Endocr. Relat. Cancer. 32, e250091 (2025)","journal-title":"Endocr. Relat. Cancer"},{"key":"4470_CR61","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00259-007-0691-z","volume":"35","author":"B De Keizer","year":"2008","unstructured":"De B. Keizer, Van M.O. Aken, R.A. Feelders, De W.W. Herder, B.L.R. Kam et al., Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur. J. Nucl. Med. Mol. Imaging. 35, 749\u2013755 (2008)","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"4470_CR62","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","volume":"14","author":"J Klawitter","year":"2015","unstructured":"J. Klawitter, B. Nashan, U. Christians, Everolimus and sirolimus in transplantation-related but different. Expert Opin. Drug Saf. 14, 1055\u20131070 (2015)","journal-title":"Expert Opin. Drug Saf."},{"key":"4470_CR63","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin et al., Everolimus for advanced pancreatic neuroendocrine tumors. N Engl. J. Med. 364, 514\u2013523 (2011)","journal-title":"N Engl. J. Med."},{"key":"4470_CR64","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1310967","volume":"370","author":"S Senniappan","year":"2014","unstructured":"S. Senniappan, S. Alexandrescu, N. Tatevian, P. Shah, V. Arya et al., Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia. N Engl. J. Med. 370, 1131\u20131137 (2014)","journal-title":"N Engl. J. Med."},{"key":"4470_CR65","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/jjco\/hyt193","volume":"44","author":"M Asayama","year":"2014","unstructured":"M. Asayama, T. Yamada-Murano, H. Hara, A. Ooki, M. Kurosumi et al., Everolimus dramatically improves glycemic control in unresectable metastatic insulinoma: A case report. Jpn J. Clin. Oncol. 44, 186\u2013190 (2014)","journal-title":"Jpn J. Clin. Oncol."},{"key":"4470_CR66","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","volume":"22","author":"DD Sarbassov","year":"2006","unstructured":"D.D. Sarbassov, S.M. Ali, S. Sengupta, J.-H. Sheen, P.P. Hsu et al., Prolonged Rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB. Mol. Cell. 22, 159\u2013168 (2006)","journal-title":"Mol. Cell."},{"key":"4470_CR67","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12020-020-02604-x","volume":"71","author":"V Tovazzi","year":"2021","unstructured":"V. Tovazzi, V.D. Ferrari, A. Dalla Volta, F. Consoli, V. Amoroso, A. Berruti, Should everolimus bestopped after radiological progression in metastatic insulinoma? A \u201ccons\u201d point of view. Endocrine. 71, 258\u2013258 (2021)","journal-title":"Endocrine"},{"key":"4470_CR68","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","volume":"378","author":"ME Pavel","year":"2011","unstructured":"M.E. Pavel, J.D. Hainsworth, E. Baudin, M. Peeters, D. H\u00f6rsch et al., Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 378, 2005\u20132012 (2011)","journal-title":"Lancet"},{"key":"4470_CR69","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1056\/NEJMc0806740","volume":"360","author":"MH Kulke","year":"2009","unstructured":"M.H. Kulke, E.K. Bergsland, J.C. Yao, Glycemic control in patients with Insulinoma treated with everolimus. N Engl. J. Med. 360, 195\u2013197 (2009)","journal-title":"N Engl. J. Med."},{"key":"4470_CR70","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.2169\/internalmedicine.0126-17","volume":"57","author":"S Yanagiya","year":"2018","unstructured":"S. Yanagiya, K.Y. Cho, A. Nakamura, H. Nomoto, Y. Kawamoto et al., The effect of everolimus on refractory hypoglycemia in a patient with inoperable metastatic Insulinoma evaluated by continuous glucose monitoring. Intern. Med. 57, 2527\u20132531 (2018)","journal-title":"Intern. Med."},{"key":"4470_CR71","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1634\/theoncologist.2010-0222","volume":"16","author":"H-B Fiebrich","year":"2011","unstructured":"H.-B. Fiebrich, E.J.M. Siemerink, A.H. Brouwers, T.P. Links, W.S. Remkes et al., Everolimus induces rapid plasma glucose normalization in Insulinoma patients by effects on tumor as well as normal tissues. Oncologist. 16, 783\u2013787 (2011)","journal-title":"Oncologist"},{"key":"4470_CR72","doi-asserted-by":"publisher","first-page":"278","DOI":"10.5414\/CP204503","volume":"62","author":"S Rouf","year":"2024","unstructured":"S. Rouf, K. Boujtat, T.E. Harroudi, H. Latrech, Balancing efficacy and adverse reactions using everolimus in a patient with metastatic malignant insulinoma: case report. Int. J. Clin. Pharmacol. Ther. 62, 278\u2013283 (2024)","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"4470_CR73","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000491999","volume":"107","author":"E Raymond","year":"2018","unstructured":"E. Raymond, M.H. Kulke, S. Qin, X. Yu, M. Schenker et al., Efficacy and safety of Sunitinib in patients with Well-Differentiated pancreatic neuroendocrine tumours. Neuroendocrinology. 107, 237\u2013245 (2018)","journal-title":"Neuroendocrinology"},{"key":"4470_CR74","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"E. Raymond, L. Dahan, J.-L. Raoul, Y.-J. Bang, I. Borbath et al., Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl. J. Med. 364, 501\u2013513 (2011)","journal-title":"N Engl. J. Med."},{"key":"4470_CR75","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1586\/era.13.45","volume":"13","author":"J Chen","year":"2013","unstructured":"J. Chen, C. Wang, J. Han, Y. Luan, Y. Cui et al., Therapeutic effect of Sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic Insulinoma. Expert Rev. Anticancer Ther. 13, 737\u2013743 (2013)","journal-title":"Expert Rev. Anticancer Ther."},{"key":"4470_CR76","doi-asserted-by":"publisher","first-page":"438","DOI":"10.14310\/horm.2002.1560","volume":"14","author":"A Fountas","year":"2015","unstructured":"A. Fountas, S. Tigas, Z. Giotaki, D. Petrakis, G. Pentheroudakis et al., Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on Sunitinib treatment. Hormones. 14, 438\u2013441 (2015)","journal-title":"Hormones"},{"key":"4470_CR77","doi-asserted-by":"publisher","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","volume":"19","author":"MH Shah","year":"2021","unstructured":"M.H. Shah, W.S. Goldner, A.B. Benson, E. Bergsland, L.S. Blaszkowsky et al., Neuroendocrine and adrenal Tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw. 19, 839\u2013868 (2021)","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"4470_CR78","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","volume":"39","author":"MH Kulke","year":"2010","unstructured":"M.H. Kulke, L.B. Anthony, D.L. Bushnell, De W.W. Herder, S.J. Goldsmith et al., NANETS treatment guidelines: Well-Differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 39, 735\u2013752 (2010)","journal-title":"Pancreas"},{"key":"4470_CR79","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1046\/j.1365-2265.2002.01506.x","volume":"56","author":"A Scott","year":"2002","unstructured":"A. Scott, D. Hinwood, R. Donnelly, Radio-frequency ablation for symptom control in a patient with metastatic pancreatic Insulinoma: Radio-frequency ablation in Insulinoma. Clin. Endocrinol. (Oxf). 56, 557\u2013559 (2002)","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"4470_CR80","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/01.SMJ.0000091035.18498.47","volume":"97","author":"T-H Tran","year":"2004","unstructured":"T.-H. Tran, R.D. Pathak, A.L.P. Basa, Metastatic insulinoma: case report and review of the literature. South. Med. J. 97, 199\u2013201 (2004)","journal-title":"South. Med. J."},{"key":"4470_CR81","first-page":"e253","volume":"34","author":"J.C. Maiza","year":"2011","unstructured":"J.C. Maiza, D. Vezzosi, S. Grunenwald, P. Otal, R. Guimbaud et al., Treatment with somatostatin analogs and chemoembolization of liver metastases for severe hypoglycemia in malignant insulinomas. J. Endocrinol. Invest. 34, e253\u2013e258 (2011)","journal-title":"J. Endocrinol. Invest."},{"key":"4470_CR82","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/oncolo\/oyad327","volume":"29","author":"W Badar","year":"2024","unstructured":"W. Badar, Q. Yu, M. Patel, O. Ahmed, Transarterial radioembolization for management of hepatocellular carcinoma. Oncologist. 29, 117\u2013122 (2024)","journal-title":"Oncologist"},{"key":"4470_CR83","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.2967\/jnumed.112.105361","volume":"53","author":"L Uliel","year":"2012","unstructured":"L. Uliel, H.D. Royal, M.D. Darcy, D.A. Zuckerman, A. Sharma et al., From the angio suite to the \u03b3-Camera: vascular mapping and99m Tc-MAA hepatic perfusion imaging before liver Radioembolization\u2014A comprehensive pictorial review. J. Nucl. Med. 53, 1736\u20131747 (2012)","journal-title":"J. Nucl. Med."},{"key":"4470_CR84","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"M. Pavel, K. \u00d6berg, M. Falconi, E.P. Krenning, A. Sundin et al., Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 844\u2013860 (2020)","journal-title":"Ann. Oncol."},{"key":"4470_CR85","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.3390\/cancers14143415","volume":"14","author":"K Ramdhani","year":"2022","unstructured":"K. Ramdhani, A.J.A.T. Braat, The evolving role of radioembolization in the treatment of neuroendocrine liver metastases. Cancers. 14, 3415 (2022)","journal-title":"Cancers"},{"key":"4470_CR86","doi-asserted-by":"crossref","unstructured":"Y.-S. Guan, Q. He, M.-Q. Wang, (2012) Transcatheter Arterial Chemoembolization: History for More than 30 Years. ISRN Gastroenterol 2012: 1\u20138","DOI":"10.5402\/2012\/480650"},{"key":"4470_CR87","unstructured":"C. Molvar, A. Lipnik, D. Brown, R. Lewandowski, Transarterial Treatment of Liver Metastatic Neuroendocrine Tumors"},{"key":"4470_CR88","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1007\/s00330-017-4856-2","volume":"27","author":"D Do Minh","year":"2017","unstructured":"D. Do Minh, J. Chapiro, B. Gorodetski, Q. Huang, C. Liu et al., Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. Eur. Radiol. 27, 4995\u20135005 (2017)","journal-title":"Eur. Radiol."},{"key":"4470_CR89","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1245\/s10434-016-5591-7","volume":"24","author":"M Dhir","year":"2017","unstructured":"M. Dhir, R. Shrestha, J.L. Steel, J.W. Marsh, A. Tsung et al., Initial treatment of unresectable neuroendocrine tumor liver metastases with transarterial chemoembolization using streptozotocin: A 20-Year experience. Ann. Surg. Oncol. 24, 450\u2013459 (2017)","journal-title":"Ann. Surg. Oncol."},{"key":"4470_CR90","doi-asserted-by":"publisher","first-page":"CS103","DOI":"10.12659\/MSM.881891","volume":"17","author":"AF Hagel","year":"2011","unstructured":"A.F. Hagel, W.H. Hagel, A.S. Lindner, F.J. Kammerer, M.F. Neurath et al., Metastatic insulinoma \u2013 prolonged survival after multimodal approach. Med. Sci. Monit. 17, CS103\u2013CS107 (2011)","journal-title":"Med. Sci. Monit."},{"key":"4470_CR91","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00268-005-7743-y","volume":"29","author":"A Starke","year":"2005","unstructured":"A. Starke, C. Saddig, L. Mansfeld, R. Koester, C. Tschahargane et al., Malignant metastatic Insulinoma\u2014Postoperative treatment and Follow-up. World J. Surg. 29, 789\u2013793 (2005)","journal-title":"World J. Surg."},{"key":"4470_CR92","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/MPA.0000000000001569","volume":"49","author":"P Habibollahi","year":"2020","unstructured":"P. Habibollahi, H.X. Bai, S. Sanampudi, M.C. Soulen, M. Dagli, Effectiveness of Liver-Directed therapy for the management of intractable hypoglycemia in metastatic Insulinoma. Pancreas. 49, 763\u2013767 (2020)","journal-title":"Pancreas"},{"key":"4470_CR93","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s12328-023-01824-8","volume":"16","author":"T Terashima","year":"2023","unstructured":"T. Terashima, T. Yamashita, N. Takemura, A. Inaki, A. Shimizu et al., A case of frequent hypoglycemic attacks successfully controlled with capecitabine plus Temozolomide and 177Lu-DOTATATE peptide receptor radionuclide therapy in a patient with recurrent pancreatic Insulinoma. Clin. J. Gastroenterol. 16, 767\u2013771 (2023)","journal-title":"Clin. J. Gastroenterol."},{"key":"4470_CR94","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1055\/s-0044-1788735","volume":"23","author":"Y Edamadaka","year":"2024","unstructured":"Y. Edamadaka, R.V. Parghane, S. Basu, Aggressive metastatic Insulinoma in a patient of diabetes mellitus with Documentation on Dual-Tracer PET-CT ([68Ga]Ga-DOTATATE and [18F]FDG): clinical benefits with combined Chemo-PRRT approach. World J. Nucl. Med. 23, 312\u2013316 (2024)","journal-title":"World J. Nucl. Med."},{"key":"4470_CR95","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000514339","volume":"112","author":"JE Rogers","year":"2022","unstructured":"J.E. Rogers, M. Lam, D.M. Halperin, C.G. Dagohoy, J.C. Yao et al., Fluorouracil, doxorubicin with Streptozocin and subsequent therapies in pancreatic neuroendocrine tumors. Neuroendocrinology. 112, 34\u201342 (2022)","journal-title":"Neuroendocrinology"},{"key":"4470_CR96","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.4103\/0973-1482.188293","volume":"14","author":"F Karatas","year":"2018","unstructured":"F. Karatas, S. Sahin, A. Aytekin, M.B. Hacioglu, G.I. Imamoglu et al., Durable complete response with a short course of streptozotocin plus doxorubicin combination in malignant metastatic Insulinoma. J. Cancer Res. Ther. 14, 1149\u20131151 (2018)","journal-title":"J. Cancer Res. Ther."},{"key":"4470_CR97","doi-asserted-by":"crossref","unstructured":"F. Gon\u00e7alves, D. Duarte, C.R. Silva, (2024) A Rare and Aggressive Case of Malignant Insulinoma. Cureus","DOI":"10.7759\/cureus.73719"},{"key":"4470_CR98","doi-asserted-by":"publisher","first-page":"oyae275","DOI":"10.1093\/oncolo\/oyae275","volume":"30","author":"U Masharani","year":"2025","unstructured":"U. Masharani, S. Lindsay, F. Moon, A. Paciorek, E. Bergsland, Metastatic insulinoma\u2014outcomes in the current era. Oncologist. 30, oyae275 (2025)","journal-title":"Oncologist"},{"key":"4470_CR99","doi-asserted-by":"publisher","first-page":"e8152","DOI":"10.1002\/ccr3.8152","volume":"11","author":"VS Buddhavarapu","year":"2023","unstructured":"V.S. Buddhavarapu, G. Dhillon, H.S. Grewal, B. Soles, L. Halbur et al., Transformation of pancreatic nonfunctioning neuroendocrine tumor into metastatic insulinoma: A rare case report. Clin. Case Rep. 11, e8152 (2023)","journal-title":"Clin. Case Rep."},{"key":"4470_CR100","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12328-013-0437-3","volume":"6","author":"Y Kiyozumi","year":"2013","unstructured":"Y. Kiyozumi, H. Takamori, O. Nakahara, Y. Ikuta, A. Chikamoto et al., Hepatic arterial infusion combined with systemic chemotherapy induced complete response of metachronous liver metastases after resection of pancreatic Insulinoma. Clin. J. Gastroenterol. 6, 496\u2013499 (2013)","journal-title":"Clin. J. Gastroenterol."},{"key":"4470_CR101","doi-asserted-by":"publisher","first-page":"e1772","DOI":"10.1136\/bmjspcare-2021-003188","volume":"14","author":"L Simkiss","year":"2024","unstructured":"L. Simkiss, F. Hakkak, R. Raghavan, Malignant Insulinoma hypoglycaemia: complex palliative management. BMJ Support Palliat. Care. 14, e1772\u2013e1774 (2024)","journal-title":"BMJ Support Palliat. Care"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04470-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04470-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04470-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T03:02:51Z","timestamp":1770087771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04470-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4470"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04470-x","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Written informed consent was obtained from the patient for publication of the radiological images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"58"}}